-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Benzinga·08/20/2026 15:35:36
Listen to the news
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.